Renaissance Technologies's BMY Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 3.67 M shares of Bristol-Myers Squibb Company (BMY) worth $165.41 M, representing 0.22% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in BMY, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2019, adding 27.45 M shares. Largest reduction occurred in Q2 2020, reducing 22.49 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Bristol-Myers Squibb Company (BMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bristol-Myers Squibb Company (BMY) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +8.53 M | Add 0.00% | 8.53 M | $44.69 |
| Q3 2013 | -4.19 M | Reduce 49.14% | 4.34 M | $46.28 |
| Q4 2013 | -4.3 M | Reduce 99.05% | 41,200 | $53.16 |
| Q1 2014 | +1.45 M | Add 3521.01% | 1.49 M | $51.95 |
| Q2 2014 | +967,345 | Add 64.84% | 2.46 M | $48.51 |
| Q3 2014 | -2.19 M | Reduce 88.98% | 270,900 | $51.18 |
| Q4 2014 | +27,600 | Add 10.19% | 298,500 | $59.03 |
| Q1 2015 | +175,600 | Add 58.83% | 474,100 | $64.50 |
| Q2 2015 | -474,100 | Sold Out | 474,100 | $0.00 |
| Q2 2016 | +537,000 | New Buy | 537,000 | $73.55 |
| Q3 2016 | +4.2 M | Add 782.72% | 4.74 M | $53.92 |
| Q4 2016 | -4.14 M | Reduce 87.41% | 597,000 | $58.44 |
| Q1 2017 | +5.87 M | Add 983.42% | 6.47 M | $54.38 |
| Q2 2017 | +7.02 M | Add 108.54% | 13.49 M | $55.72 |
| Q3 2017 | -2.64 M | Reduce 19.58% | 10.85 M | $63.74 |
| Q4 2017 | +3.46 M | Add 31.87% | 14.3 M | $61.28 |
| Q1 2018 | +225,400 | Add 1.58% | 14.53 M | $63.25 |
| Q2 2018 | -3.98 M | Reduce 27.40% | 10.55 M | $55.34 |
| Q3 2018 | -1.2 M | Reduce 11.41% | 9.34 M | $62.08 |
| Q4 2018 | -2.4 M | Reduce 25.65% | 6.95 M | $51.98 |
| Q1 2019 | +5.4 M | Add 77.79% | 12.35 M | $47.71 |
| Q2 2019 | +8.35 M | Add 67.58% | 20.7 M | $45.35 |
| Q3 2019 | +12.06 M | Add 58.26% | 32.76 M | $50.71 |
| Q4 2019 | +27.45 M | Add 83.81% | 60.21 M | $64.19 |
| Q1 2020 | +5.78 M | Add 9.60% | 65.99 M | $55.74 |
| Q2 2020 | -22.49 M | Reduce 34.09% | 43.5 M | $58.80 |
| Q3 2020 | -12.92 M | Reduce 29.70% | 30.58 M | $60.29 |
| Q4 2020 | -12.1 M | Reduce 39.56% | 18.48 M | $62.03 |
| Q1 2021 | -11.51 M | Reduce 62.27% | 6.97 M | $63.13 |
| Q2 2021 | +333,738 | Add 4.79% | 7.31 M | $66.82 |
| Q3 2021 | -185,000 | Reduce 2.53% | 7.12 M | $59.17 |
| Q4 2021 | -2.08 M | Reduce 29.21% | 5.04 M | $62.35 |
| Q1 2022 | -2.41 M | Reduce 47.76% | 2.63 M | $73.03 |
| Q2 2022 | -1.81 M | Reduce 68.78% | 822,018 | $77.00 |
| Q3 2022 | -822,018 | Sold Out | 822,018 | $0.00 |
| Q4 2022 | +657,200 | New Buy | 657,200 | $0.07 |
| Q1 2023 | +487,100 | Add 74.12% | 1.14 M | $0.07 |
| Q2 2023 | +65,100 | Add 5.69% | 1.21 M | $0.06 |
| Q3 2023 | -180,546 | Reduce 14.93% | 1.03 M | $58.04 |
| Q4 2023 | +1.4 M | Add 136.40% | 2.43 M | $51.31 |
| Q1 2024 | -2.43 M | Sold Out | 2.43 M | $0.00 |
| Q3 2024 | +908,538 | New Buy | 908,538 | $51.74 |
| Q4 2024 | +151,995 | Add 16.73% | 1.06 M | $56.56 |
| Q1 2025 | +1.01 M | Add 95.57% | 2.07 M | $60.99 |
| Q2 2025 | +1.41 M | Add 67.84% | 3.48 M | $46.29 |
| Q3 2025 | +186,556 | Add 5.36% | 3.67 M | $45.10 |
Renaissance Technologies's Bristol-Myers Squibb Company Investment FAQs
Renaissance Technologies first purchased Bristol-Myers Squibb Company (BMY) in Q2 2013, acquiring 8,530,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Bristol-Myers Squibb Company (BMY) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to Bristol-Myers Squibb Company (BMY) was in Q4 2019, adding 60,210,661 shares worth $3.86 B. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 3,667,689 shares of Bristol-Myers Squibb Company (BMY), valued at approximately $165.41 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bristol-Myers Squibb Company (BMY) represents approximately 0.22% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in Bristol-Myers Squibb Company (BMY) was 65,992,111 shares, as reported at the end of Q1 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.